Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics

被引:49
作者
Slayter, KL
Ludwig, EA
Lew, KH
Middleton, E
Ferry, JJ
Jusko, WJ
机构
[1] SUNY BUFFALO,SCH PHARM,DEPT PHARMACEUT,BUFFALO,NY 14260
[2] SUNY BUFFALO,SCH PHARM,DEPT PHARM,BUFFALO,NY 14260
[3] SUNY BUFFALO,SCH MED,DEPT MED,BUFFALO,NY 14260
[4] BUFFALO GEN HOSP,DEPT PHARM,BUFFALO,NY 14203
[5] BUFFALO GEN HOSP,DEPT MED,BUFFALO,NY 14203
[6] UPJOHN CO,KALAMAZOO,MI 49001
关键词
D O I
10.1016/S0009-9236(96)80009-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Oral contraceptive (OC) steroids alter the disposition of numerous drugs, including corticosteroids, We investigated the pharmacokinetics and pharmacodynamics of methylprednisolone. Methods: Twelve women (six women used OC steroids and six women did not) received intravenous methylprednisolone (0.6 mg/kg ideal body weight), Methylprednisolone disposition was assessed from plasma concentrations, Pharmacodynamic parameters measured were plasma cortisol, whole blood histamine (reflecting basophils), and blood helper T lymphocytes. Results: Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours), With use of indirect response models, significant differences were observed with the cortisol and basophil responses, A larger value for the concentration that inhibits the zero-order production rate by 50% (0.37 versus 0.11 ng/ml) was observed in the women who used OC steroids for suppression of cortisol secretion, indicating less sensitivity to the suppressive effects of methylprednisolone. Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng hr/ml). No differences were observed for helper T-cell responses. Conclusion: OC steroids appear to inhibit methylprednisolone metabolism, However, mixed changes in several responses occur, indicating that women can probably receive similar doses of methylprednisolone irrespective of OC steroid use.
引用
收藏
页码:312 / 321
页数:10
相关论文
共 38 条
[1]   IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].
ABERNETHY, DR ;
TODD, EL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428
[2]   IMPAIRMENT OF DIAZEPAM METABOLISM BY LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVE STEROIDS [J].
ABERNETHY, DR ;
GREENBLATT, DJ ;
DIVOLL, M ;
ARENDT, R ;
OCHS, HR ;
SHADER, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (13) :791-792
[3]   PHARMACOKINETIC DRUG-INTERACTIONS WITH ORAL-CONTRACEPTIVES [J].
BACK, DJ ;
ORME, MLE .
CLINICAL PHARMACOKINETICS, 1990, 18 (06) :472-484
[4]   PREDNISOLONE DISPOSITION AND PROTEIN-BINDING IN ORAL-CONTRACEPTIVE USERS [J].
BOEKENOOGEN, SJ ;
SZEFLER, SJ ;
JUSKO, WJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (04) :702-709
[5]   BIOLOGICALLY ACTIVE CORTISOL IN PLASMA OF OESTROGEN-TREATED AND NORMAL SUBJECTS [J].
BURKE, CW .
BRITISH MEDICAL JOURNAL, 1969, 2 (5660) :798-&
[6]   ANTIPYRINE ELIMINATION IN SALIVA AFTER LOW-DOSE COMBINED OR PROGESTOGEN-ONLY ORAL-CONTRACEPTIVE STEROIDS [J].
CHAMBERS, DM ;
JEFFERSON, GC ;
CHAMBERS, M ;
LOUDON, NB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (02) :229-232
[7]   ELEVATED NONPROTEIN-BOUND CORTISOL (NPC) IN PREGNANCY, DURING ESTROGEN ADMINISTRATION AND IN CARCINOMA OF PROSTATE [J].
DOE, RP ;
DICKINSO.P ;
ZINNEMAN, HH ;
SEAL, US .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1969, 29 (06) :757-+
[8]   PHARMACOKINETICS AND PHARMACODYNAMICS OF METHYLPREDNISOLONE IN OBESITY [J].
DUNN, TE ;
LUDWIG, EA ;
SLAUGHTER, RL ;
CAMARA, DS ;
JUSKO, WJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (05) :536-549
[9]   ANALYSIS OF CORTISOL, METHYLPREDNISOLONE, AND METHYLPREDNISOLONE HEMISUCCINATE - ABSENCE OF EFFECTS OF TROLEANDOMYCIN ON ESTER HYDROLYSIS [J].
EBLING, WF ;
SZEFLER, SJ ;
JUSKO, WJ .
JOURNAL OF CHROMATOGRAPHY, 1984, 305 (02) :271-280
[10]   PHARMACOIMMUNODYNAMICS OF METHYLPREDNISOLONE - TRAFFICKING OF HELPER LYMPHOCYTES-T [J].
FISHER, LE ;
LUDWIG, EA ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1992, 20 (04) :319-331